Related Experiment Videos
[The implications of thromboembolism in chronic heart failure]
V Ambăruş1, C Rezuş, Rodica Ghiuru
1Clinica a III-a Medicală Cardiologie I. Enescu, Facultatea de Medicină, Universitatea de Medicină şi Farmacie Gr.T. Popa, Iaşi.
Insights
Long-term anticoagulant therapy significantly reduces mortality in heart failure patients. This treatment lowers the risk of death by 70%, primarily by preventing thrombembolism.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Heart failure (CHF) management often involves addressing high mortality rates.
- Thrombembolism is a primary cause of death in CHF patients.
Purpose:
- To investigate the impact of long-term anticoagulant therapy on mortality in patients with CHF, NYHA class III-IV.
- To compare the annual death rates between CHF patients receiving anticoagulant/antiplatelet therapy and a control group.
Summary:
- A 5-year study compared mortality in 150 CHF patients (control group) with 325 patients receiving Acenocumarol or Aspirin (treatment group).
- The control group had an annual death rate of 4% (30 deaths), while the treatment group had a 1.2% annual death rate (20 deaths).
- Mortality risk was 70% lower in the treatment group, indicating significant benefits of anticoagulant and antiplatelet therapy.
Impact:
- Anticoagulant and antiplatelet therapies are crucial for reducing mortality in CHF patients.
- These therapies mitigate the risk associated with thrombembolism, a major cause of death in this population.
- Findings support the essential role of anticoagulant/antiplatelet strategies in CHF management.
Abstract:
The goal of investigation was to determine whether long-term anticoagulant therapy influences the mortality rate in CHF. The method consisted in the calculation of the annual death rate of the patients with CHF class III-IV NYHA: group A (controls)--who did not receive anticoagulant or antiplatelet therapy; group B--treated with Acenocumarol or Aspirin. The results show in group A, which included 150 patients, during the 5-year interval under study 30 deaths, representing an annual death rate of 4%. In group B, which included 325 patients of which 75 treated with Acenocumarol and 250 patients with aspirin, 20 deaths were recorded during the same 5-year interval, representing an annual death rate of 1.2%. Thus, the mortality risk proved to be 70% lower in group B than in the control group. It came out that the main mechanism of death in CHF is thrombembolism and in this circumstance anticoagulant or antiplatelet therapy would be essential.